

Pharmacy and Therapeutics Committee Meeting
September 9th, 2003
Kellogg Hotel and Conference Center

Draft Minutes

Committee Members in Attendance

Giovanino Perri, M.D., Chairman (for this meeting)
Robert Coffey, PharmD
Debera Eggleston, M.D.
Jonathan Henry, M.D.
Edward Keating, RPh.
Max Robins, D.O.

Committee Members Not in Attendance

Robert Ernst, M.D.
David Johnson, M.D.

Community Health Representatives in Attendance

George Baker, M.D.; Chief Medical Consultant, Children's Special Health Care Services
Paul Reinhart, Director, Medical Services Administration
Bradley Sprecher, Pharmacy Section Analyst

First Health Services Corporation Representatives in Attendance

Annette Paul, RPh, Clinical Manager for Michigan Medicaid

Audience

Approximately 50 persons in attendance

Proceedings

- I. Meeting called to order at 6:07 P.M. by Dr. Perri.
- II. Paul Reinhart noted staffing changes within the Department's Pharmacy Unit. Dave McLaury is to handle First Health contractual issues while Dr. Perri will handle clinical issues.

III. Dr. Perri mediated the public comments, including presentations from the following (in the order in which they appeared):

- Dr. Ryan Arnold: Enbrel
- Dr. Michael Carella: New Insulin, Lispro 70/30, Novolog 70/30 Aspart
- Kathleen Bovid: ABSENT
- Dr. Michelle Minshew: PPI/PA Policy
- Earl Crosby, Dr. Susan Wood: Aggrenox
- Anil Votkur: Prevacid Solutab
- Dr. Justice Fiechner: Humira
- Dr. Clyde Cooper: Innopran
- Archie Shew, Dr. Ken Murphy: Tamiflu
- Dr. Keith Aaronson: Coreg
- Dr. David Neff: Zocor
- Dr. Al Masterson: Strattera
- Dr. Gary Stein: Avelox

IV. Approval of Minutes

The Minutes of the June 3rd Meeting were accepted as written.

V. New Product Review

Annette Paul provided a clinical review of Humira.

The Committee moved to accept Humira as a covered product without restrictions.

VI. Issues for Committee Consideration

Strattera

The Committee moved to cover Strattera without prior authorization, except for patients below age 6.

PPI Policy

The Committee moved and accepts the motion to continue the PA on 40 mg Protonix after 102 days of use, consistent with current clinical monitoring.

A motion to accept the supplemental rebate offer for Prevacid Solutab is tabled for consideration at the December meeting. PA numbers will be monitored during the intervening period.

Grandfathering

Dr. Perri asked the Committee to review its email communication to see that the grandfathering provisions implemented subsequent to the June 3rd meeting are consistent with their memory of the meeting.

Carvedilol

Dr. Perri asks if there is a motion to move Coreg to preferred status.

The Committee moves to consider the issue at a later date, after more information is reviewed.

VII. The meeting adjourns at 9:30 P.M.

Next Meeting is Tuesday, December 2nd, 2003

6:00 P.M. – 9:00 P.M.

Kellogg Hotel and Conference Center

Respectfully submitted by Brad Sprecher